Search results for "Immuno-PET"

showing 2 items of 2 documents

Development and in vitro evaluation of new bifunctional 89Zr-chelators based on the 6-amino-1,4-diazepane scaffold for immuno-PET applications

2021

Abstract Introduction Combination of hydroxamate bearing side chains with the 6-amino-1,4-diazepane scaffold provides a promising strategy for fast and stable 89Zr-labeling of antibodies. Following this approach, we hereby present the development, labeling kinetics and in vitro complex stability of three resulting bifunctional chelator derivatives both stand-alone and coupled to a model protein in comparison to different linear deferoxamine (DFO) derivatives. Methods The novel 89Zr-chelator Hy3ADA5 was prepared via amide-coupling of separately synthesized 6-amino-1,4-diazepane-6-pentanoic acid and hydroxamate-containing side chains. Two further bifunctional derivatives were synthesized by e…

Cancer ResearchKinetics[CHIM.THER]Chemical Sciences/Medicinal ChemistryDeferoxamine030218 nuclear medicine & medical imaging03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHybrid-chelatormedicineMoietyRadiology Nuclear Medicine and imagingChelationBifunctionalAntibodyHydroxamic acidChemistrySquaramideZirconium-89Combinatorial chemistryIn vitroDeferoxamineHydroxamic acid030220 oncology & carcinogenesisImmuno-PETMolecular Medicinemedicine.drugNuclear Medicine and Biology
researchProduct

89 Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89 Zr Radiochemistry

2017

Contains fulltext : 181624.pdf (Publisher’s version ) (Open Access) Immuno-positron emission tomography (immunoPET) with (89)Zr-labeled antibodies has shown great potential in cancer imaging. It can provide important information about the pharmacokinetics and tumor-targeting properties of monoclonal antibodies and may help in anticipating on toxicity. Furthermore, it allows accurate dose planning for individualized radioimmunotherapy and may aid in patient selection and early-response monitoring for targeted therapies. The most commonly used chelator for (89)Zr is desferrioxamine (DFO). Preclinical studies have shown that DFO is not an ideal chelator because the (89)Zr-DFO complex is partly…

Pathologymedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentmonoclonal-antibodiesBiomedical Engineeringrational designPharmaceutical Sciencebifunctional chelating-agentBioengineeringCancer imagingReviewgrowth-factorRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]010402 general chemistryMonoclonal antibody01 natural sciencesDose planningp-isothiocyanatobenzyl-desferrioxamineIn vivo[ CHIM.ORGA ] Chemical Sciences/Organic chemistryimmuno-petmedicineIn patient[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyPharmacologymedicine.diagnostic_test010405 organic chemistrybusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryOrganic Chemistrydrug development3. Good health0104 chemical sciencesDrug developmentPositron emission tomographyRadioimmunotherapyUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]click chemistryCancer researchmetastatic breast-cancerbusinessbearing nude-miceNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]BiotechnologyBioconjugate Chemistry
researchProduct